GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » Cyclically Adjusted PS Ratio

Aurobindo Pharma (BOM:524804) Cyclically Adjusted PS Ratio : 2.50 (As of Jun. 04, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Aurobindo Pharma Cyclically Adjusted PS Ratio?

As of today (2025-06-04), Aurobindo Pharma's current share price is ₹1144.20. Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹457.55. Aurobindo Pharma's Cyclically Adjusted PS Ratio for today is 2.50.

The historical rank and industry rank for Aurobindo Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:524804' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.08   Med: 2.39   Max: 3.59
Current: 2.48

During the past years, Aurobindo Pharma's highest Cyclically Adjusted PS Ratio was 3.59. The lowest was 1.08. And the median was 2.39.

BOM:524804's Cyclically Adjusted PS Ratio is ranked worse than
55.01% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs BOM:524804: 2.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aurobindo Pharma's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹144.374. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹457.55 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurobindo Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Aurobindo Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cyclically Adjusted PS Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.89 1.98 1.35 2.56 2.53

Aurobindo Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 2.76 3.26 2.94 2.53

Competitive Comparison of Aurobindo Pharma's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cyclically Adjusted PS Ratio falls into.


;
;

Aurobindo Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aurobindo Pharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1144.20/457.55
=2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Aurobindo Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=144.374/157.5517*157.5517
=144.374

Current CPI (Mar. 2025) = 157.5517.

Aurobindo Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 56.489 99.841 89.141
201509 57.575 101.753 89.147
201512 59.961 102.901 91.806
201603 64.078 102.518 98.476
201606 64.326 105.961 95.645
201609 64.832 105.961 96.398
201612 66.702 105.196 99.899
201703 62.238 105.196 93.214
201706 62.789 107.109 92.360
201709 75.697 109.021 109.393
201712 74.041 109.404 106.626
201803 69.105 109.786 99.171
201806 72.570 111.317 102.712
201809 81.118 115.142 110.996
201812 88.287 115.142 120.805
201903 88.754 118.202 118.300
201906 91.411 120.880 119.143
201909 94.176 123.175 120.459
201912 98.980 126.235 123.535
202003 103.495 124.705 130.755
202006 99.258 127.000 123.136
202009 108.795 130.118 131.733
202012 108.419 130.889 130.504
202103 102.276 131.771 122.287
202106 97.135 134.084 114.136
202109 100.477 135.847 116.531
202112 102.212 138.161 116.558
202203 98.880 138.822 112.221
202206 105.372 142.347 116.627
202209 96.859 144.661 105.490
202212 108.967 145.763 117.780
202303 108.803 146.865 116.720
202306 115.884 150.280 121.491
202309 121.165 151.492 126.012
202312 124.567 152.924 128.336
202403 128.364 153.035 132.153
202406 127.293 155.789 128.733
202409 130.963 157.882 130.689
202412 135.875 158.323 135.213
202503 144.374 157.552 144.374

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurobindo Pharma  (BOM:524804) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aurobindo Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines